INCY · NASDAQ · Biotechnology

Incyte (INCY)

Developer of Jakafi, Opzelura, and targeted hematology, oncology, and immune-disease medicines.

$126.93
After hours+0.02 (+0.02%)
At close$126.91(+1.81%)